NASDAQ: ERASErasca Inc Stock Ownership - Who owns Erasca?
Insider buying vs selling
Have Erasca Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Shannon Morris | Chief Medical Officer | 2026-03-04 | 20,000 | $1.70 | $34.00kBuy |
| Shannon Morris | Chief Medical Officer | 2026-03-04 | 20,000 | $15.04 | $300.76kSell |
| Ebun Garner | General Counsel Corp. Sec. | 2026-01-07 | 120,000 | $1.70 | $204.00kBuy |
| Ebun Garner | General Counsel Corp. Sec. | 2026-01-07 | 120,000 | $5.59 | $670.80kSell |
| David M. Chacko | CFO and CBO | 2025-12-15 | 17,793 | $1.19 | $21.24kBuy |
| Ebun Garner | General Counsel Corp. Sec. | 2025-12-15 | 3,902 | $1.19 | $4.66kBuy |
ERAS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ERAS insiders and whales buy or sell their stock.
ERAS Shareholders
What type of owners hold Erasca Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Jonathan E. Lim | 20.09% | 62,451,152 | $911.79M | Insider |
| Frazier Life Sciences Management LP | 7.31% | 22,729,436 | $331.85M | Institution |
| Vr Adviser LLC | 5.75% | 17,857,083 | $260.71M | Institution |
| T Rowe Price Investment Management Inc | 5.18% | 16,111,414 | $235.23M | Institution |
| Blackrock Inc | 5.02% | 15,597,330 | $227.72M | Institution |
| Suvretta Capital Management LLC | 4.67% | 14,502,004 | $211.73M | Institution |
| Paradigm Biocapital Advisors LP | 4.56% | 14,159,095 | $206.72M | Institution |
| Logos Global Management LP | 4.18% | 13,000,000 | $189.80M | Institution |
| Vanguard Group Inc | 4.12% | 12,812,156 | $187.06M | Institution |
| Arch Venture Partners X LLC | 3.56% | 11,055,554 | $161.41M | Insider |
ERAS vs Biotech Stocks
Erasca Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.